share_log

Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart

Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart

希望的金十字出现在BioMarin制药的图表上
Benzinga Real-time News ·  2022/08/09 11:16

If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

如果历史可以借鉴的话,苹果的股票可能会有好运气BioMarin制药公司(纳斯达克:宝马)。在它的图表上已经形成了一个所谓的“黄金十字”,并不令人惊讶,这可能对该股有利。

What To Know: Many traders use moving average crossover systems to make their decisions.

要知道的内容:许多交易员使用移动平均线交叉系统来做出决定。

When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term average price, it means the trend is lower.

当短期平均价格超过长期平均价格时,可能意味着该股正在走高。如果短期均价低于长期均价,则意味着走势更低。

Why It's Important: The 50-day and the 200-day simple moving averages are commonly used.

为什么它很重要:常用的是50日和200日简单移动均线。

The golden cross occurs when the 50-day crosses above the 200-day. This could mean the long-term trend is changing.

当50天线在200天线上方时,黄金十字就会出现。这可能意味着长期趋势正在改变。

That just happened with Biomarin Pharmaceutical, which is trading around $96.18 at publication time.

这种情况就发生在BioMarin制药公司身上,该公司在出版时的股价约为96.18美元。

Remember: Seasoned investors don't blindly trade Golden Crosses.

记住:经验丰富的投资者不会盲目交易金十字。

Instead, they use it as a signal to start looking for long positions based on other factors, like price levels and company fundamentals & events.

相反,他们把它作为一个信号,开始根据其他因素寻找多头头寸,比如价格水平和公司基本面和事件。

For seasoned investors, this is just a sign that it might be time to start considering possible long positions.

对于经验丰富的投资者来说,这只是一个迹象,表明可能是时候开始考虑可能的多头头寸了。

With that in mind, take a look at Biomarin Pharmaceutical's past and upcoming earnings expectations:

考虑到这一点,让我们来看看BioMarin制药公司过去和即将到来的收益预期:

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate 0.11   -0.32 -0.25
EPS Actual 0.59 0.17 -0.32 -0.20
Revenue Estimate 521.47M 507.52M 442.39M 435.32M
Revenue Actual 533.80M 519.36M 449.81M 408.74M
季度 Q2 2022 Q1 2022 Q4 2021 Q3 2021
每股收益预估 0.11 -0.32 -0.25
实际每股收益 0.59 0.17 -0.32 -0.20
收入预估 521.47M 507.52M 442.39M 435.32M
实际收入 533.80M 519.36M 449.81M 408.74M

Also consider this overview of Biomarin Pharmaceutical analyst ratings:

另请考虑BioMarin制药分析师评级的概述:

Do you use the Golden Cross signal in your trading or investing? Share this article with a friend if you found it helpful!

你在交易或投资中使用金十字信号吗?如果你觉得这篇文章对你有帮助,那就和朋友分享吧!

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自动内容引擎生成,并由编辑审阅。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发